-
The authors performed a descriptive analysis of all cases of desquamative inflammatory vaginitis (DIV), defined as symptomatic vaginitis (discharge, dyspareunia, pruritus, burning, or irritation) associated with vaginal inflammation (such as focal or linear erosions), a vaginal pH higher than 4.5, and saline microscopy showing an increase in parabasal and inflammatory cells in the absence of an infectious etiology (such as trichomonas, candida, or bacterial vaginosis).
-
-
Understanding sexual pain remains limited. with multiple etiologies and lack of evidence-based outcomes research, future investigations should focus on evaluating the intimacy of the couple, the partner relationship, and biomedical sources of pain such as the pelvic floor muscles.
-
Uterine leiomyosarcomas (LMS) rarely are suspected preoperatively unless there has been documented rapid growth of the uterus or evidence of extrauterine disease.
-
Dealing with a question about certain dietary items in pregnancy sometimes is daunting because often there is no consensus regarding a proper answer.
-
Baseline and 6-month data were collected on morbidly obese women who planned to undergo weight reduction surgery.
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
Deep vein thrombosis (DVT) and pulmonary embolus (PE) occur more frequently in patients with cancer, and the risk appears to vary by tumor type.
-
In a Phase 3 trial comparing the recently introduced monoclonal antibody denosumab with zoledronic acid for the treatment of patients with prostate cancer metastatic to bone, the incidence of skeletal events including pathological fracture, radiation, skeletal surgery, or cord compression was delayed on average by more than 3 months for those treated with denosumab. Adverse events were comparable. Denosumab is administered subcutaneously and can be given to patients with renal insufficiency. Clinicians have become familiar with zoledronic acid in this setting, and it remains unclear whether its role as the standard approach will be supplanted.
-
Investigators prospectively assessed quality of life in newly diagnosed AML patients 60 years and older using the EORTC QLC-C30 and QOL-E surveys. Among the 113 patients enrolled, 42.4% underwent intensive induction chemotherapy and 57.6% received palliative treatment. Self-rated quality of life did not correlate with physician-rated performance status or induction chemotherapy. Lower self-report functional status predicted higher mortality, even after adjusting for age, treatment, and comorbidity. Patient-reported quality of life may be an independent prognostic factor for AML outcomes.